Innovotech Investor Presentation December 1, 2010

1. Innovotech Inc.Pursuing the Greatest Opportunityin Microbiology Since Penicillin On the Radar 1 December 2010

2. Forward Looking Statements This presentation contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Forward-looking statements may include words such as “expects”, “plans”, “will”, “believes”, “estimates”, “intends”, “may”, and other words of similar meaning and may relate to future financial performance, business strategies, or safety and efficacy of unapproved products. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; availability and cost of raw materials; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company’s exposure to lawsuits and other matters beyond the control of management.

4. The natural state of bacteria

5. Plaque on teeth

6. Scum in shower

7. Cause 80% of human infections

8. Up to 1000x more resistant

9. No antibiotics, disinfectants or diagnostics approved for biofilms

11. Market Opportunity

12. Technology Platform DIAGNOSTIC Products: bioFILM PA™, Gram +/-ve test TREATMENT Products: Agress®, Sani-Lux™,AgreGuard™

14. Clinical and health economic evaluation at University of Alberta Cystic Fibrosis clinic – 3 lives saved

15. Sick Kids (Toronto) trial showing different antibiotic selections 71% of time compared to traditional testing

16. Partner with established market players

17. LevPharm Ltd – Hospital distributor in Israel

18. Regulatory

19. Health Canada approval

22. Environmental concerns

23. For bioFILM PA™

24. Empirical (educated guess)

25. For Agress®

28. 2004

29. 2006

30. 2007

31. 2010- Began trading on the Toronto Venture Exchange (TSX-V: IOT) - Completed Qualifying Transaction by acquiring University of Calgary technology - Amalgamation of Innovotech and MBEC BioProducts - Consolidation of operations in Edmonton - 21 employees in 3600 sq. ft. facility - Two products in advanced stages of development

33. Former-Chairman, Foundation Equity Corporation, a successful technology venture capital firm.

34. Partner with Parlee McLaws LLP, specializing in intellectual property and technology development.

35. Executive in pharmaceutical manufacturing at Laporte PLC, Degussa GmbH and Rhodia Pharma Solutions. CEO of Raylo Chemicals.

36. Founding Partner, St Arnaud Pinsent, Steman a technology-focused chartered accounting firm. Former Director of Technology at Ernst and Young LLP.

37. Experience in the creation, management, and financing of knowledge-based companies. Former-Chair & CEO of Innovotech, Raylo Chemicals and Cytovax Biotechnologies.

39. World recognized biofilm expert. Experienced researcher and entrepreneur holding over 35 patents in medical and veterinary science and over 170 published papers. Inventor of the MBEC Assay™ and founder of MBEC Biofilm Technologies.

40. Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies.Ken Boutilier, MBA President and CEO Merle Olson, DVM Research Director Jim Timourian, PhD Chief Financial Officer

41. Product Pipeline One platform technology – many products Phase of Development Market Introduction Regulatory Research & Development bioFILM PA™ Agress® Sani-Lux™ Gram +/-ve test AgreGuard™ Product *AgreGuard™ is a Silver technology for coating catheters; Sani Lux™ is a hard surface disinfectant

43. Low overheads

44. R&D expenditures - $550,000*

45. Burn rate - $82,000/month

46. Cash - $936,000*

47. Shares outstanding – 24M** As of September 30, 2010

49. “Green”, and effective agricultural product

50. Strong pipeline based on a single technology platform

51. Revenue“All current microbiology may have to be reinvented to meet the needs of biofilm microbiology.”

52. Contact Information Ken Boutilier, President Innovotech Inc. ken.boutilier@innovotech.ca Ph: 780-448-0585 ext 221 Fax: 780-424-0941